Sirnaomics Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 36
Employees
  • Latest Deal Type
  • IPO
  • (Upcoming)
  • Investors
  • 20

Sirnaomics General Information

Description

Developer of novel targeted therapeutics intended to treat critical human diseases. The company's therapeutics leverage proprietary Polypeptide Nano-Particle (PNP) technology to access the tumor micro-environment (TME), as well as various cell types in the liver, enabling medical practitioners to treat patients effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • 401 Professional Drive
  • Suite 280
  • Gaithersburg, MD 20879
  • United States
+1 (301) 000-0000

Sirnaomics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sirnaomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. IPO Upcoming Generating Revenue
11. Later Stage VC (Series D) 31-Dec-2020 00000 00000 00000 Completed Generating Revenue
10. Debt - PPP 13-Apr-2020 000.00 Completed Generating Revenue
9. Later Stage VC (Series C1) 06-Jun-2018 0000 000.00 Completed Generating Revenue
8. Later Stage VC (Series C) 16-Mar-2018 000.00 000.00 00000 Completed Generating Revenue
7. Later Stage VC (Series B) 28-Apr-2016 0000 000.00 0000 Completed Generating Revenue
6. Grant 25-Jun-2012 00000 00000 Completed Startup
5. Grant 29-Jun-2010 00000 00000 Completed Startup
4. Grant 22-Jul-2009 $250K $808K Completed Startup
3. Early Stage VC (Series A) 14-Apr-2009 $650K $808K 00.000 Completed Startup
To view Sirnaomics’s complete valuation and funding history, request access »

Sirnaomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series C 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 00.000
Series B 7,374,632 $0.001000 $0.2 $1.36 $1.36 1x $1.36 7.7%
Series A 2,024,860 $0.001000 $0.03 $0.33 $0.33 1x $0.33 2.11%
To view Sirnaomics’s complete cap table history, request access »

Sirnaomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel targeted therapeutics intended to treat critical human diseases. The company's therapeutics leverage
Drug Discovery
Gaithersburg, MD
36 As of 2021
00000
000

00000000

ng elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
Middleton, WI
00 As of 0000
000.00
0000000000 0 000.00

00000000

sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sirnaomics Competitors (53)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
000000 00000000 Venture Capital-Backed Williamsville, NY 00 00.000 000000000 - 00.000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 53 competitors. Get the full list »

Sirnaomics Executive Team (15)

Name Title Board Seat Contact Info
Patrick Lu Ph.D Co-Founder, Chief Executive Officer, President & Chairman
Allan Shaw Chief Financial Officer
George Ji Co-Founder & Chief Operation Officer
Dmitry Samarsky Ph.D Chief Technology Officer
David Evans Ph.D Co-Founder & Chief Scientific Officer
You’re viewing 5 of 15 executive team members. Get the full list »

Sirnaomics Board Members (8)

Name Representing Role Since
Da Liu Self Board Member 000 0000
Michael Molyneaux MD Sirnaomics Chief Medical Officer & Board Member 000 0000
Mike Ghias Sirnaomics Board Member 000 0000
Mongcong Huang Sirnaomics Board Member 000 0000
Patrick Lu Ph.D Sirnaomics Co-Founder, Chief Executive Officer, President & Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Sirnaomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sirnaomics Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alpha Win Capital Venture Capital Minority 000 0000 000000 0
Cachet Asset Management Asset Manager Minority 000 0000 000000 0
China Resources Capital Management Corporate Venture Capital Minority 000 0000 000000 0
Hongtao Capital Venture Capital Minority 000 0000 000000 0
Legend Sky Investment Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Sirnaomics Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 21-Apr-2021 0000 00000 0000 Drug Discovery
RNAimmune 24-Aug-2020 Seed Round 00.000 Drug Discovery
To view Sirnaomics’s complete investments history, request access »